XHANCE is the first and only approved treatment for people suffering from chronic sinusitis without nasal polyps. Doctors emphasize that this system is considered very safe for most patients. As with ...

LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.

In a new clinical practice guideline, recommendations are presented for the surgical management of chronic rhinosinusitis in adults.

In patients with chronic rhinosinusitis with nasal polyps, factors including baseline antibiotic use and asthma impacted the ...

An estimated 30 million American adults grapple with the discomfort of chronic sinusitis, a condition that makes the simple act of breathing a challenge for about one in eight adults.

Shares of Lyra Therapeutics, Inc. (LYRA) rocketed 370% on Monday after the company announced positive results from its ...

Lyra also reported success on key secondary endpoints. These included improvements in broader symptom scores and patient ...

Lyra's LYR-210 met key goals in a Phase 3 trial for chronic rhinosinusitis, showing early and sustained symptom relief with a ...

Lyra Therapeutics stock surged in premarket trading after announcing positive Phase 3 trial results for a key treatment.

Lyra Therapeutics (NASDAQ:LYRA) saw its stock soar by 180% after releasing encouraging Phase 3 results for its lead ...

For instance, people in their 30s and 40s may develop nasal polyps, benign (noncancerous) growths. These growths are often linked to inflammation in the nose lining, a condition known as chronic ...

The TikToker claimed that her bare-butted significant other at the time let out a particularly smelly fart that led chronic ...